



Regulatory T Lymphocytes: Three Decades with Odette-and-Odile in Human Diseases

Guest Editor:

**Dr. Maria-Ioanna (Marianna)
Christodoulou**

1. Department of Life Sciences,
European University Cyprus,
Nicosia 2404, Cyprus
2. School of Infection and
Immunity, University of Glasgow,
Glasgow G12 8TA, UK

Deadline for manuscript
submissions:

31 May 2024

Message from the Guest Editor

Dear Colleagues,

Responses of the immune system are controlled by regulatory mechanisms guided by specific immunoreactive and suppressive cellular compartments, including regulatory lymphocytes, macrophages, and myeloid-derived suppressor cells. The first described immune cell population with regulatory properties was the regulatory T cells (Tregs), almost 30 years ago. Since the first report on their implication in the development of autoimmunity in experimental models, Tregs have attracted great research interest and have been proven pivotal players in any condition where the control of immune response may be critical.

In vivo and in vitro experiments have revealed their implication in the development and perpetuation of human disorders in the fields of autoimmunity, cancer, allergy, asthma, and others, and indicated their potential as possible therapeutic targets. In this commemorative Special Issue, we welcome submissions of research works on the involvement of Tregs in any human disorder where the immune microenvironment plays a key pathogenetic role, and/or on their capacity to enhance the diagnostic and therapeutic clinical armamentarium.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)